Scientists found that the protein promotes survival of KMT2A-rearranged leukemia, presenting a previously unappreciated vulnerability. Read more: https://www.stjude.org/media-resources/news-releases/2026-medicine-science-news/mbnl1-identified-as-potential-cancer-drug-target-for-type-of-childhood-leukemia.html

In a study, Black and Hispanic parents were largely willing to enroll children in oncology trials, while clinicians cited hardship and gatekeeping as barriers. Read more: https://www.cancernetwork.com/view/what-limits-pediatric-oncology-trial-access-for-marginalized-families-

Researchers at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are zeroing in on less toxic and more targeted strategies to combat Ewing sarcoma, an aggressive and rare pediatric cancer that develops in the bones and soft tissues. Read more: https://medicalxpress.com/news/2026-08-biochemists-strategy-combat-pediatric-bone.html

Few young adults receive palliative care (PC) as part of treatment for stage 4 solid tumors or poor-prognosis high-grade brain tumors, according to a research letter published online July 23 in JAMA Network Open. Read more: https://www.oncologynurseadvisor.com/news/few-young-adults-receive-palliative-care-as-part-of-advanced-cancer-treatment/

A new scientific breakthrough may soon mean hope for children and families facing one of pediatric cancer’s deadliest foes. Instead of targeting viruses or bacteria, this new mRNA vaccine is setting its sights on an aggressive childhood tumor: neuroblastoma. Read more: https://www.futura-sciences.com/en/a-childhood-cancer-faces-a-new-enemy-this-mrna-vaccine-isnt-for-viruses_36759/

Adult childhood cancer survivors (CCS) of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) frequently report mental distress, fatigue and executive function (EF) impairment, according to a study published online in Current Oncology. Read more: https://medicalxpress.com/news/2026-07-mental-distress-fatigue-common-childhood.html

Nearly half of childhood tumors treated with common types of chemotherapy showed detectable DNA changes linked to treatment within 18 months, according to a new international study led by The Hospital for Sick Children (SickKids). Researchers say these changes could eventually help clinicians spot treatment resistance earlier, before cancer returns or spreads, opening the door to a more precise use of chemotherapy. Read more: https://www.news-medical.net/news/20260723/Chemot

Scientists from St. Jude Children’s Research Hospital and collaborators have identified the RNA-binding protein RBM5 as a potential vulnerability in a set of difficult-to-treat childhood leukemias. Read more: https://www.stjude.org/media-resources/news-releases/2026-medicine-science-news/targeting-rbm5-may-help-disrupt-undruggable-myc-in-childhood-leukemia.html

Among Ewing sarcoma (EWS) survivors, rates of late mortality, subsequent malignant neoplasms (SMNs), and certain chronic health conditions (CHCs) do not significantly differ between 2 chemotherapy regimens, according to research published in Cancer. Read more: https://www.cancertherapyadvisor.com/news/ewing-sarcoma-survivors-elevated-long-term-health-mortality-risks/

Now, a new Phase 1 trial led by researchers at Children’s National Hospital showed that a new autologous multi-antigen T cell therapy can be delivered intravenously and reach the brain through the bloodstream to fight off brain tumors in children. Read more: https://www.drugdiscoverynews.com/new-autologous-t-cell-therapy-offers-hope-for-children-with-brain-tumors-17325